Implication of β2-adrenergic receptor and miR-196a correlation in neurite outgrowth of LNCaP prostate cancer cells

PLoS One. 2021 Jun 30;16(6):e0253828. doi: 10.1371/journal.pone.0253828. eCollection 2021.

Abstract

The β2-adrenergic receptor has been shown to be involved in neuroendocrine differentiation and to contribute to the development of aggressive prostate cancer. In this study we have investigated whether miR-196a plays a role in the regulation of the β2-adrenergic receptor in the LNCaP prostate cancer cell line. Our results show that the expression of miR-196a is elevated in LNCaP prostate cancer cells with reduced levels of β2-adrenergic receptor after stably transfection with three different shRNAs. Furthermore, treatment with β-blockers showed that this upregulation is strictly related to the low levels of β2-adrenergic receptor and not to the inhibition of the receptor signaling activity. Finally, we found that the reduced ability of LNCaP cells with low levels of β2-adrenergic receptor to initiate neuroendocrine differentiation under androgen depletion conditions is mediated by miR-196a. In conclusion, this study provides the rational for a role of miR-196a in the β2-adrenergic receptor mediated neuroendocrine differentiation of LNCaP prostate cancer cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-2 Receptor Antagonists
  • Cell Line, Tumor
  • Gene Expression Regulation, Neoplastic*
  • Gene Knockdown Techniques
  • Humans
  • Male
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*
  • Neuronal Outgrowth / drug effects
  • Neuronal Outgrowth / genetics*
  • Prostate / pathology
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology
  • Receptors, Adrenergic, beta-2 / genetics*
  • Receptors, Adrenergic, beta-2 / metabolism
  • Up-Regulation

Substances

  • ADRB2 protein, human
  • Adrenergic beta-2 Receptor Antagonists
  • MIRN196 microRNA, human
  • MicroRNAs
  • Receptors, Adrenergic, beta-2

Grants and funding

This work was funded by The South-Eastern Norwegian Regional Health Authority (22811; 2016043) The Norwegian Research Council, The Norwegian Cancer Society, The University of Oslo and Oslo University Hospital. Ilaria Guerriero was funded by a “Fondazione Umberto Veronesi Travel Grant (2019)”.